BioHealthonomics is a pharmaceutical company developing a proprietary, industry unique technology for the treatment and prevention of migraine headaches.
Raised to Date: Raised: $36,600
Aggregate Commitments $
Equity - Common
Rolling Commitments $
BioHealthonomics is here to help. They are a pharmaceutical company developing an industry unique technology for the treatment and prevention of migraine headaches. Their technology addresses the root cause of the problem by targeting the histamine receptors found to be involved in migraine headaches. People susceptible to migraines have a tendency to release excess histamine when introduced to a stressor or trigger, which is what causes the headache. BioHealthonomics’ treatment helps prevent that release of excess histamine from happening. Less histamine means less migraines -- and who doesn’t want that?
So far, clinical studies have found their treatment works in over 80% of migraine patients, versus the traditional migraine treatment of using CGRP antibodies, which only works in 50% of patients. BioHealthonomics believes their technology is superior to CGRP antibodies both in terms of safety efficacy and cost standpoints, and they have a clear path for continuing to develop an extremely effective, side effects free treatment.
So far, they have two issued patents in the U.S. and patents pending in five additional markets. They’ve also entered into a strategic agreement with another pharmaceutical company to gain access to pre-clinical, phase I clinical, and chemistry, manufacturing, and controls data. This will save millions of dollars in development costs, as well as years in development time.
Migraines are the sixth most disabling disorder in the U.S., with over 30 million people suffering from them. In fact, $50 billion is lost each year because of medical expenses caused by headaches, reduced employee productivity, and absenteeism. The migraine product market is currently $3.4 billion, with projections to grow up to $10 billion in the next decade, and BioHealthonomics, with their industry unique treatment, is poised to be the leader in this market.
You could truly be on your way to being headache free. BioHealthonomics has the technology to make that dream a reality. A life without migraines….just imagine all of the possibilities.
“Who Should Be Interested in this Offer:”
If you’re someone who suffers from migraines, or if someone close to you does, then BioHealthonomics is worth your attention. They are offering a solution that addresses the root of the problem and has proven to be more successful than current available treatments. If you want to say goodbye to migraines (and possibly profit at the same time!), then investing in BioHealthonomics might just be the headache-free choice for you.
Upgrade to gain access
- Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- , plus
- Company specific
- Advanced company search ( )
- Get Edge Annual
- Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- In-depth risk ratings for every raise
- Get Edge Pro Annual